- Home
- TNGX vs PEB Comparison
TNGX vs PEB Comparison
Compare TNGX & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | PEB |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | TNGX | PEB |
|---|---|---|
| Price | $9.11 | $11.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 9 |
| Target Price | ★ $12.50 | $12.28 |
| AVG Volume (30 Days) | ★ 2.8M | 1.8M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 0.36% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $66,501,000.00 | ★ $1,464,126,000.00 |
| Revenue This Year | $53.01 | $2.32 |
| Revenue Next Year | N/A | $2.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.29 | 0.99 |
| 52 Week Low | $1.03 | $7.42 |
| 52 Week High | $11.20 | $15.12 |
Technical Indicators
Market Signals| Indicator | TNGX | PEB |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 55.96 |
| Support Level | $8.88 | $10.67 |
| Resistance Level | $10.22 | $11.58 |
| Average True Range (ATR) | 0.69 | 0.36 |
| MACD | -0.13 | -0.00 |
| Stochastic Oscillator | 22.04 | 70.54 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.